Q2 2025 Business Update

*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.

Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy

To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.

●	FAP-Dox (AVA6000), a pre\|CISION^®-enabled form of doxorubicin chemotherapy, continues to progress in Phase 1b studies. During the second quarter, patient enrollment continued across the expansion cohorts, with early signs of efficacy observed, including a robust partial response in a patient with salivary gland cancer, with a nearly 50% reduction in tumor diameters. We remain on track to release the initial data in salivary gland cancer in late 2025 and in triple negative breast cancer in H1 2026.
●	FAP-EXd (AVA6103), a pre\|CISION^®-enabled PDC comprised of the pre\|CISION^® peptide linked to exatecan, continues preclinical development. AVA6103 is currently in investigational new drug (IND)-enabling studies with a Phase 1 trial anticipated to begin in the first quarter of 2026.
●	Multiple Data Presentations at the American Association for Cancer Research (AACR) Annual Congress. In April Avacta presented three posters at the AACR Annual Meeting, showcasing continued progress across its pipeline. These included an update from the salivary gland cancer cohort of the Phase 1a trial of FAP-Dox (AVA6000), with sustained durable responses observed in multiple patients. Notably, median progression free survival (PFS) had not yet been reached after a follow-up of 5.9 months, nearly double that reported in published benchmark data (Licitra et a. ESMO 2024). The two additional presentations featured preclinical data from Avacta's second agent, FAP-EXd (AVA6103), along with translational work with the proprietary pre\|CISION^® platform. Further updates on the next generation peptide drug conjugates (PDCs) are expected later in 2025.
●	We continue to engage with third parties across a range of commercial opportunities reflecting the breadth of the pre\|CISION^® platform and progressing these discussions remains a top priority. We are also discussing FAP-Dox with a range of parties who are keen to assess additional data which is due later this year and in H1 2026.

Companies

UK 100

Latest directors dealings